Floatz logo

Midostaurin

AML (Adult) With t (8; 21) (q22; q22)

David IberriSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the AML (Adult) With t (8; 21) (q22; q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Alice Mims
Phase 3BBB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 3BBB
Idarubicine
The First Affiliated Hospital of Soochow University
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →